Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Sep;71(9):7110-3.
doi: 10.1128/JVI.71.9.7110-7113.1997.

Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions

Affiliations

Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions

T Dorfman et al. J Virol. 1997 Sep.

Abstract

Human immunodeficiency virus type 1 (HIV-1) incorporates the cellular peptidyl-prolyl cis-trans isomerase cyclophilin A (CyPA), the cytosolic receptor for the immunosuppressant cyclosporin A (CsA). CsA inhibits the incorporation of CyPA and reduces HIV-1 virion infectivity but is inactive against closely related primate lentiviruses that do not interact with CyPA. The incorporation of CyPA into HIV-1 virions is mediated by a specific interaction with a proline-containing, solvent-exposed loop in the capsid (CA) domain of the Gag polyprotein. CsA, which disrupts the interaction with CA, binds at the active site of CyPA. To test whether active-site residues are also involved in the interaction with HIV-1 CA, we used a panel of previously characterized active-site mutants of human CyPA. Expression vectors for epitope-tagged wild-type and mutant CyPA were transfected into COS-gamma cells along with HIV-1 proviral DNA, and the virions produced were analyzed for the presence of tagged proteins. Cotransfection of the wild-type expression vector led to the incorporation of readily detectable amounts of epitope-tagged CyPA into HIV-1 virions. One CyPA mutant with a substantially decreased sensitivity to CsA was incorporated with wild-type efficiency, demonstrating that the requirements for binding to CsA and to HIV-1 CA are not identical. The remaining six CyPA mutants were incorporated with markedly reduced efficiency, providing in vivo evidence that HIV-1 CA interacts with the active site of CyPA.

PubMed Disclaimer

References

    1. Science. 1984 Nov 2;226(4674):544-7 - PubMed
    1. Mol Cell Biol. 1988 Jan;8(1):466-72 - PubMed
    1. Nature. 1989 Feb 2;337(6206):473-5 - PubMed
    1. Nature. 1989 Feb 2;337(6206):476-8 - PubMed
    1. Science. 1991 Jan 18;251(4991):283-7 - PubMed

Publication types

LinkOut - more resources